KR100381214B1 - Imidazolidine-2,4-dione derivatives useful as anticancer agents and preparation method thereof - Google Patents

Abstract

The present invention provides an imidizolidine-2,4-dione derivative of formula (1) capable of inhibiting panesyl transferase, stereochemical isomers thereof, pharmaceutically acceptable salts and esters thereof, methods for preparing the same, and The present invention relates to an anticancer composition comprising a compound as an active ingredient.

[Formula 1]

In the above formula,

R ¹ , R ² and R ³ are as defined in the specification.

Description

Imidazolidine-2,4-dione derivatives useful as anticancer agents and methods for preparing the same

The present invention relates to an imidazolidine-2,4-dione derivative of the formula (1) or a pharmaceutically acceptable salt thereof.

Formula 1

In the above formula,

R ₁ is aromatic; Aromatic substituted by lower alkyl; Aromatic substituted by halogen; Bicyclic aromatics; Aromatics including nitrogen or sulfur factors; Or lower alkyl substituted by aromatic,

R ₂ represents an amino acid group or any one selected from the group of the following structural formulas;

From here,

A is 1) hydrogen; 2) lower alkyl; 3) aromatic substituted by halogen, cyano, nitro, carboxylate (COOR), amide, thioamide, sulfanyl (SP), alkoxy (OR) or lower alkyl; 4) aromatics containing nitrogen or sulfur atoms in the ring substituted by halogen, cyano, nitro, COOR, amide, thioamide, SR or lower alkyl: 5) lower alkyl substituted by aromatics of 3) or 4) above (In SP, OR and COOR, R means hydrogen or lower alkyl); Or 6) group Indicates,

From here,

E represents hydrogen or FG, where F represents CH ₂ , C═O or SO ₂ , and G is lower alkyl unsubstituted or substituted by hydrogen, phenyl or biphenyl; Lower alkoxy; Phenyl; benzyl; Benzyloxy or amino unsubstituted or substituted by lower alkyl, phenyl, benzyl cycloalkyl or phenoxyalkyl,

B and C each independently represent hydrogen, halogen or lower alkyl,

n represents 0 to 4,

R3 is hydrogen, lower alkyl or group Indicates,

From here,

D is alkoxy, hydroxy, amino, morpholine, thiomorpholine, piperazine unsubstituted or substituted by lower alkyl, alkoxyalkylamine substituted or unsubstituted by lower alkyl, unsubstituted or substituted by lower alkyl Phenoxyalkylamine, alkylamine or amino acid residue unsubstituted or substituted by lower alkylamino,

m represents 0-2.

The present invention also includes a method for preparing the compound of Formula 1 and an anticancer composition containing the compound of Formula 1 as an active ingredient. Therefore, the manufacturing method and composition are the object of this invention.

Ras protein is a 21 kda protein that plays an important role in cell growth and differentiation. It is an enzyme that binds guanine nucleotides and hydrolyzes guanosine triphosphate (GTP) to guanosine diphosphate (GDP). It is known to act as a molecular switch that regulates the GTPase circuit (Bourne, HR; Sanders, D. A: McCormick, F. Nature, 1991, 349, 117).

Ras proteins are produced in mammalian cells by the three Ras genes as amino acids 188 K-Ras-4B or 189 H-Ras, K-ras4A and N-Ras. The amino acids at positions 12, 13 and 61 of the protein are in close proximity to the phosphate groups of GTP, and these amino acid residues inhibit GTP enzymatic activity by affecting the spatial position of water molecules involved in the hydrolysis of GTP. In cancers occurring in the human body, mutations of amino acids at this position are observed, which eventually leads to GTP binding due to inhibition of Ras protein-specific GTP enzyme activity, resulting in carcinogenicity by continuously transmitting abnormal growth signals. It is known to become. This carcinogenic Ras gene is specifically known to be closely related to pancreatic cancer, bladder cancer, lung cancer and skin cancer (Bos, J.L., Cancer Res., 1989, 49, 4682). In addition, Ras protein has been reported to be involved in the growth of vascular smooth muscle cells and is known to be closely related to atherosclerosis and diabetes mellitus (cf. JP H7-112930).

In order for the Ras protein to be biologically active, it must be attached to the cell membrane, which requires post-protein transfer by Ras farnesyl transferase, three AAX peptide cleavage enzymes at the Ras protein carboxy terminus, methyl transferase and palmitoyl transferase. Carbon end modifications are required. The first step, panesylation, is achieved by farnesyl transferase (FTase). The substrate of the farnesyl transferase is four peptides, CA1A2X, at the carboxy terminus of the Ras protein, where A1 and A2 are aliphatic amino acids with no electrical load and X is methionine, alanine and serine. This farnesyl reaction occurs on cysteine to form a sulfur ether bond, and in the case of H-Ras and N-Ras, palmitoylation occurs on another cysteine near the carboxy terminus. As a result of the panesylation, the Ras protein is increased in affinity and adheres to the cell membrane, and the panesylated Ras protein is successively removed from the carboxy terminus by three AAX peptides and is methylated so that the panesyl groups are separated from the lipid layer or the cell membrane. It is known to facilitate binding with other receptors. On the other hand, k-Ras-4B, unlike H-Ras and N-Ras, has a site in which several lysine bases, called poly basic domains, are arranged in place of cysteine required for paldytoylation. It is known to facilitate binding with anionic lipids. All modification steps are necessary to optimally attach the Ras protein in the cell membrane. However, the activity of the Ras protein is known to be sufficient by panesylation alone, and studies to inhibit Ras carcinogenic activity by mutations by blocking the panesylation are actively conducted. Ongoing (Buss, JE et al., Chemistry & Biology, 1995, 2, 787).

Previous studies have shown that inhibition of farnesyl transferase in Ras-transformed cells has been shown to inhibit cell growth and improves the cell traits modified by Ras.

Indeed, several inhibitors of farnesyl transferase have been shown to selectively inhibit the response of Ras oncogenic genes to intracellular prenyl groups (see Kohl, N E. et al, Proc. Natl. Acad. Sci, USA). , 1994, 9, 9141, Kohl, NE et al, Nature Medicine, 1995, 1, 792. The developed panesyl transferase inhibitors include a peptide variant containing a cysteine thiol group and a structure similar to CAAX, and an inhibitor that improves the same (see US Patent 5, 141.851; Kohl, NE et al., Science. 1993, 260. 1934). Graham et al. PCT / US95 / 12224.), Peptides whose backbone structure is modified with phenyl groups (Sebti, SM, J. Biol. Chem., 1995, 270, 26802), benzodiazepines in psychotropic pharmaceutical backbones Modified using the structure of the peptide as a turn simulation structure (Science, 1993, 260, 1937), inhibitors based on tricyclic organic compounds deviating from the peptide structure (Bishop WR, J. Biol. Chem., 1995 , 270, 30611). In addition, studies of inhibitors that mimic the catalysis step of panesyl transferase require a positive load on the transition state because the mechanism of action of the transfer of the panesyl transfer enzyme to the prenyl group is an electrophilic displacement reaction. With this in mind, a new type of inhibitor was proposed which linked the positive load of the transition state to the prenyl group (Pouiter CD et al, J. Am. Chem. Soc., 1996, 118, 8761).

Accordingly, the present inventors have continued to develop compounds having structural characteristics that can simulate the transition state of the farnesyl transferase, and the faresyl transfer by simulating the transition state of the farnesyl transferase. A novel compound capable of inhibiting the action of the enzyme was synthesized and its inhibitory ability was evaluated. As a result, the present inventors have found that the imidazolidine-2,4-dione of the formula (1) meets the intended purpose of the present invention and that they can be usefully used as a cancer-causing agent.

Accordingly, the present invention relates to an imidazolidine-2,4-dione derivative of the formula (1) having excellent anticancer effect by inhibiting the activity of farnesyl transferase, and a preparation method thereof.

The present invention also relates to an anticancer composition comprising an imidazolidine-2,4-dione derivative of formula (I) as an active ingredient.

The present invention relates to an imidazolidine-2,4-dione derivative of Formula 1, a stereochemically isomer thereof, a pharmaceutically acceptable salt or ester thereof having an anticancer effect by inhibiting the activity of a panesyl transferase:

Formula 1

In the above formula,

R ₁ is aromatic; Aromatic substituted by lower alkyl; Aromatic substituted by halogen; Bicyclic aromatics; Aromatics containing nitrogen or sulfur atoms; Or lower alkyl substituted by aromatic,

R ₂ represents an amino acid group or any one selected from the group of the following structural formulas;

From here,

A is 1) hydrogen; 2) lower alkyl; 3) aromatic substituted by halogen, cyano, nitro, carboxylate (COOR), amide, thioamide, sulfanyl (SR), alkoxy (OR) or lower alkyl; 4) aromatics containing nitrogen or sulfur atoms substituted by halogen, cyano, nitro, COOR, amide, thioamide, SR or lower alkyl in the ring; 5) lower alkyl substituted by the aromatic of 3) or 4) above (R in SR, OR and COOR means hydrogen or lower alkyl); Or 6) group Indicates,

From here,

E represents hydrogen or FG, wherein F represents CH ₂ , C═O or SO ₂ , and G is lower alkyl unsubstituted or substituted by hydrogen, phenyl or biphenyl; Lower alkoxy; Phenyl; benzyl; Benzyloxy; Or amino substituted or unsubstituted by lower alkyl, phenyl, benzyl, cycloalkyl or phenoxyalkyl,

B and C each independently represent hydrogen, halogen or lower alkyl,

n represents 0 to 4,

R3 is hydrogen, lower alkyl or group Indicates,

From here,

D is alkoxy, hydroxy, amino, morpholine, thiomorpholine, piperazine unsubstituted or substituted by lower alkyl, alkoxyalkylamine substituted or unsubstituted by lower alkyl, unsubstituted or substituted by lower alkyl Phenoxyalkylamine, alkylamine or amino acid residue unsubstituted or substituted by lower alkylamino,

m represents 0-2.

As used herein, the term "lower alkyl" refers to straight or branched chain alkyl of 1 to 4 carbon atoms, such as methyl, ethyl, isopropyl, isobutyl, t-butyl, etc., and "aromatics including nitrogen and sulfur atoms" It means a mono or bicyclic aromatic containing two to two nitrogen or sulfur atoms in the aromatic ring.

The compounds of the present invention have asymmetric carbon centers and may exist as racemates, racemic compounds and their respective stereoisomers, all of which areomers are included in the present invention.

The invention may also include compounds in the form of pharmaceutically acceptable salts, hydrates or solvates.

Representative examples of compounds of formula 1 according to the present invention are as shown in Tables 1a to 1d below:

TABLE 1a

TABLE 1b

TABLE 1c

TABLE 1d

The compound of formula 1 according to the present invention may be prepared by (a) reacting a compound of formula 2 with a compound of formula 3 by Mitsunobu to obtain a compound of formula 1; (b) reacting the compound of Formula 4 with a Mitsunobu compound with the compound of Formula 3 to obtain a compound of Formula 1a; (c) hydrolyzing the compound of formula 1a obtained in step (b) to obtain a compound of formula 1b, and then amidating by coupling in the presence of a coupling agent with a compound of formula 5 to obtain a compound of formula 1c It is also possible to prepare, and methods for preparing such compounds of Formula 1 are also an object of the present invention.

However, the preparation method of the compound according to the present invention is not limited to the following description, and can be easily prepared by arbitrarily combining various synthesis methods described herein or disclosed in the prior literature, and such combinations belong to the present invention. It is a common technique generalized to those skilled in the art.

[Formula 2]

[Formula 3]

[Formula 4]

[Formula 1a]

[Formula 1b]

[Formula 5]

[Formula 1c]

In the above formula,

R ¹ , R ² and R ³ are as defined in claim 1,

D 'is the same as D, but not hydroxy or alkoxy.

Coupling agents required for amidation in the process for preparing the compound of formula 1 according to the present invention include dicyclohexylcarbodiimide (DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiide (EDC ) And 1,1'-dicarbonyldiimidazole (CDI) and the like can be used in a mixed state with 1-hydroxybenzotriazole.

The compounds used as starting materials in the methods (a) to (c) according to the present invention can be prepared according to the methods shown in Schemes 1 to 7 below.

The compound of Formula 2 may be synthesized by performing alkylation and cyclization of amine using ethyl bromo acetate as shown in Scheme 1 below.

Scheme 1

In the above scheme, R ¹ and R ³ are as defined above.

Compounds of formula 4 can be synthesized by the methods shown in Schemes 2 and 3. The racemate can be synthesized through alkylation and cyclization of the amine with fumarate, as shown in Scheme 2. In the case of stereochemical isomers, it can be synthesized through reductive amination and cyclization reaction of aspartic acid and amide with an ester protecting group as shown in Scheme 3.

Scheme 2

In the above scheme, R ¹ is as defined above.

Scheme 3

In the above scheme, R ¹ is as defined above.

Compounds of Formula 3 can be synthesized through the following Schemes 4-7. Synthesis of imidazole using dihydroxy acetone as in Schemes 4 to 5 may be performed, or it may be synthesized by alkylating existing imidazole methanol as in Scheme 6. It can also be synthesized in the same manner as in Scheme 7.

Scheme 4

Scheme 5

Scheme 6

Scheme 7

AcOH represents acetic acid, Cbz-Cl represents benzyloxycarbonyl chloride, Trt-Cl represents chlorotriphenylmethane, and TFA represents trifluoroacetic acid.

Reaction conditions including the amount of reactants used in the present reaction, reaction temperature, reaction time, and the like can be easily determined by those skilled in the art according to a specific reactant.

In addition, the free compound of formula 1 produced in the above reaction can be converted into the salt as described above according to conventional methods known in the art.

After completion of the reaction in the process according to the invention the product can be separated and purified by conventional work-up methods such as chromatography, recrystallization and the like.

The compound of the present invention prepared according to the method as described above has an inhibitory effect on the farnesyl transferase as described above can be usefully used as an anticancer agent. Accordingly, another object of the present invention is to provide a cancer-containing composition containing a compound of formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient together with a pharmaceutically acceptable carrier.

While the total daily dose to be administered to the host in a single dose or in separate doses when administering a compound of the present invention for clinical purposes is preferably in the range of 5 to 100 mg per kg of body weight, the specific dose level for a particular patient will be the specific compound to be used. The patient's weight, sex, health status, diet, the time of administration of the drug, the method of administration, the rate of excretion, the drug mixture and the severity of the disease may vary.

The compounds of the present invention can be administered in injectable and oral formulations as desired. Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, can be prepared using suitable dispersing agents, wetting agents or suspending agents according to the known art. Solvents that can be used for this are water, Ringer's solution and isotonic NaCl solution, and sterile fixed oils are also commonly used as solvents or suspending media. Any non-irritating fixed oil may be used for this purpose, including mono-diglycerides, and fatty acids such as oleic acid may also be used in the preparation of injectables.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. Particularly, capsules and tablets are useful. Tablets and pills are preferably prepared with enteric agents. Solid dosage forms can be prepared by mixing the compound of formula 1 according to the invention with one or more inert diluents such as sucrose, lactose, starch and the like and a carrier such as a lubricant such as magnesium stearate, a disintegrant, a binder and the like.

The present invention, in particular the manufacturing methods described above, will be described in more detail based on the following preparation examples, examples and seals. However, these preparation examples, examples and experimental examples are only to help the understanding of the present invention, and the scope of the present invention in any sense is not limited thereto.

Preparation Example 1 Preparation of 1-naphthalen-1-yl-imidazolidine-2,4-dione

1-1) Preparation of (naphthalen-1-yl-amino) -acetic acid ethyl ester

19.3 g (139 mmol) of potassium carbonate was added to 200 ml of dimethylformamide and then heated until potassium carbonate dissolved. After cooling to room temperature, 8 ml (70 mmol) of ethyl bromoacetate and 10 g (70 mmol) of 1-naphthylamine were added, followed by stirring at room temperature for 48 hours. Dimethylformamide was removed by distillation under reduced pressure, and ethyl acetate was added thereto. The ethyl acetate layer was washed four times with water and then with saturated sodium chloride solution. Ethyl acetate was removed by distillation under reduced pressure, and then column chromatography was performed with a mixed solution of hexane and ethyl acetate (9: 1) to obtain 12 g (yield: 75%, molecular weight: 229) of the title compound.

1-2) Preparation of 1-naphthalen-1-yl-imidazolidine-2,4-dione

Preparation Example 1-1) 8.68 g (37.9 mmol) of the obtained compound and 6.34 g (75.8 mmol) of potassium isocyanate were added to 100 mL of acetic acid, followed by stirring at 110 ° C. for 24 hours. After removing acetic acid by distillation under reduced pressure, ethyl acetate was added, and washed three times with water, 1N hydrochloric acid solution, saturated sodium bicarbonate solution and saturated sodium hydroxide solution. Recrystallization from ethyl acetate gave 6.8 g (yield, 80%, molecular weight: 226) of the title compound.

Preparation Example 2 Preparation of [1- (naphthalen-1-ylmethyl) -2,4-dioxo-imidazolidin-5-yl] acetic acid ethyl ester

2-1) Preparation of 2-[(naphthalen-1-ylmethyl) -amino] succinic acid diethyl ester

3.12 mL (19.0 mmol) of diethylfumarate and 3.0 g (19 mmol) of 1-aminomethylnaphthalene were added to acetonitrile and then boiled under reflux for 12 hours. The acetonitrile was removed by filtration under reduced pressure, and then column chromatography was performed with a mixed solution of hexane and ethyl acetate (3: 1) to obtain 4.57 g (yield: 73%, molecular weight: 329) of the title compound.

2-2) Preparation of [1- (naphthalen-1-ylmethyl) -2,4-dioxo-imidizolidin-5-yl] acetic acid ethyl ester

4.57 g (13.9 mmol) of the compound obtained in Preparation Example 2-1) and 3.38 g (41.7 mmol) of potassium isocyanate were added to 150 mL of acetic acid, followed by stirring at 110 ° C. for 24 hours. After removing acetic acid by distillation under reduced pressure, ethyl acetate was added, and washed three times with water, 1N hydrochloric acid solution, saturated sodium bicarbonate solution and saturated sodium hydroxide solution. After ethyl acetate was removed by filtration under reduced pressure, column chromatography was performed using a mixed solution of hexane and ethyl acetate (1: 1) to obtain 3.85 g (yield: 85%, molecular weight: 326) of the title compound.

Preparation Example 3 Preparation of [1- (naphthalen-1-ylmethyl) -2,4-dioxo-imidazolidin- (5S) -yl] acetic acid methyl ester

3-1) Preparation of (2S)-[(naphthalen-1-ylmethyl) -amino] succinic acid diethyl ester

2.22 g (11.2 mmol) of (S) -dimethylaspartate hydrochloride and 1.6 mL (11.2 mmol) of 1-naphthyl aldehyde were added to 50 mL of dimethylformamide, followed by stirring for 1 hour. To this solution was added 5.0 g (22.4 mmol) of sodium triacetoxy borohydride and stirred for 4 hours. After dimethylformamide was removed by filtration under reduced pressure, ethyl acetate was added and washed with water and saturated sodium chloride solution. After ethyl acetate was removed by distillation under reduced pressure, column chromatography was performed with a mixed solution of nucleic acid and ethyl acetate (3: 1) to obtain 3.00 g (yield: 89%, molecular weight: 301) of the title compound.

3-2) Preparation of [1- (naphthalen-1-ylmethyl) -2,4-dioxo-imidazolidin (5S) -yl] acetic acid methyl ester

3.00 g (9.96 mmol) of the compound obtained in Preparation Example 3-1) and 2.2 g (26 mmol) of potassium isocyanate were added to 50 mL of acetic acid, followed by stirring at 110 ° C. for 30 minutes. After removing acetic acid by distillation under reduced pressure, ethyl acetate was added, and washed three times with water, 1N hydrochloric acid solution, saturated sodium bicarbonate solution and saturated sodium hydroxide solution. Ethyl acetate was removed by filtration under reduced pressure to obtain 2.87 g (yield: 92%, molecular weight: 312) of the title compound.

Preparation Example 4 Preparation of 4- (5-hydroxymethyl-imidazol-1-ylmethyl) -piperidine-1-carboxylic acid benzyl ester

4-1) Preparation of 4-aminomethyl-piperidine-1-carboxylic acid benzyl ester

22.2 g (0.2 mol) of 4-aminomethyl piperidine was dissolved in 250 ml of toluene, and then 21.2 g (0.2 mol) of benzaldehyde was added. The reaction was quenched under reflux for 3 hours, then the reaction was lowered to 0 ° C. and 34.2 g (0.2 mol) of benzylchloroformate was added dropwise under stirring. After the reaction was stirred for 3 hours, 1N KHSO ₄ (220 mL) was added at room temperature. The reaction was extracted three times with 200 mL ether and then the aqueous layer was basified with sodium hydroxide. The aqueous solution was treated with saturated sodium chloride and extracted three times with 100 ml of dichloromethane. The solution was dried over magnesium sulfate and distilled under reduced pressure to obtain 38 g (yield: 91%, molecular weight: 248) of the title compound.

4-2) Preparation of 4- (5-hydroxy methyl-2-mercapto-imidazol-1-ylmethyl) -piperidine-1-carboxylic acid benzyl ester

24.8 g (0.1 mol) of the compound of Preparation Example 4-1 were dissolved in 50 ml n-butanol together with 6.0 g (0.1 mol) of acetic acid, and then 12.6 g (0.13 mol) of potassium thiocyanate, 1.3-dihydride. 15.2 g (0.1 mol) of roxiacetone dimer and 10.0 g (0.17 mol) of acetic acid were added to a solution dissolved in 50 ml of n-butanol and stirred for 48 hours. After stirring, the solvent was distilled under reduced pressure, 200 ml of ethyl acetate was added thereto, and the mixture was washed three times with 100 ml of water. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure distillation to obtain 27 g (yield 75%, molecular weight: 361) of the title compound.

4-3) Preparation of 4- (5-hydroxymethyl-imidazol-1-ylmethyl) -piperidine-1-carboxylic acid benzyl ester.

18.05 g (50 mmol) of the compound of Preparation Example 2-2 were added to 100 ml 10% nitric acid and 10 ml solution of ethyl acetate, and the reaction was cooled with ice cold water and stirred at room temperature for 3 hours. The reaction was basified with 4N aqueous sodium hydroxide solution and extracted twice with 100 ml of ethyl acetate. The extracted organic solution was dried over magnesium sulfate and distilled under reduced pressure to obtain 12.3 g (yield 75%, molecular weight 329) of the title compound.

Preparation Example 5 Preparation of 1- (4-bromobenzyl) -5-hydroxymethyl-imidazole

After dissolving 8.9 g (40 mmol) of 4-bromobenzylamine hydrochloride salt and 4 ml of acetic acid in 85 ml n-butanol, 5.19 g (50 mmol) of potassium thiocyanate, 3.21 g of 1.3-dihydroxyacetone dimer (20 mmol) was added and stirred for 4 days. The precipitated solid was obtained by filtration under reduced pressure, and then washed with water and ethyl ester. The obtained solid was added to 10% nitric acid solution and stirred for 3 hours. After insoluble impurities were removed by filtration under reduced pressure, the solution was basified with 4N sodium hydroxide to precipitate the product. The solid was washed several times with water and dried in vacuo to give 6.7 g (yield: 60%, molecular weight: 266) of the title compound.

Preparation Example 6 Preparation of 4- (5-hydroxymethyl-imidazol-1-ylmethyl) -benzonitrile

6-1) Preparation of 1-trityl-4-hydroxymethyl-imidazole

7.98 g (59.2 mmol) of hydroxymethylimidazole hydrochloride was dissolved in 60 mL of dimethylformamide and 20 mL of triethylamine, followed by 18.7 g (67 mmol) of dimethylformamide of 200 mg of triphenylmethyl chloride. The solution was added slowly. After 2 hours 1000 ml of ice water was added to give the resulting solid. This solid was recrystallized from dioxane to give 17.6 g (yield: 87%, molecular weight: 340) of the title compound.

mp 227-229 ° C.

6-2) Preparation of 1-trityl-4-hydroxymethyl-imidazole acetate

10.00 g (29.4 mmol) of the compound of Preparation Example 6-1) were added to 200 ml of pyridine, and then 3.30 g (32.4 mmol) of acetic anhydride was added thereto, followed by stirring at room temperature for 24 hours. After distillation under reduced pressure, pyridine was removed and dissolved in 400 ml of ethyl acetate, followed by washing with 220 ml of saturated sodium chloride. The organic solvent was removed by distillation under reduced pressure and chromatographed with dichloromethane / methanol to give 10.44 g (yield 93%, molecular weight: 382) of the title compound.

6-3) Preparation of 1-trityl-3- (4-cyanobenzyl) -imidazol-4-ylmethyl acetate bromide

After dissolving 10.00 g (26.2 mmol) of the compounds of Preparation Example 6-2 in 40 mL of dichloromethane, 5.64 g (28.8 mmol) of 4-cyanobenzylbromide was added thereto, and the mixture was stirred at room temperature for 60 hours. The organic solvent was removed by distillation under reduced pressure, and column chromatography was performed with dichloromethane / methanol to give 10.62 g (yield: 70%, molecular weight: 578) of the title compound.

6-4) Preparation of 1- (4-cyanobenzyl) -imidazol-5-ylmethyl acetate

9.10 g (15.7 mmol) of the compound of step 6-3) were dissolved in 500 mL of dichloromethane, and 6.06 mL (78.7 mmol) of trifluoroacetic acid and 12.5 mL (78.7 mmol) of triethylsilane were slowly added at 0 ° C, and room temperature Stirred for 1 h. The organic solvent was removed by distillation under reduced pressure, the pH was adjusted to 10 with saturated potassium carbonate solution, and extracted with 300 ml of ethyl acetate. The organic solvent was distilled off under reduced pressure, and column chromatography was performed with ethyl acetate to obtain 3.60 g (yield: 90%, molecular weight: 255) of the title compound.

6-5) Preparation of 4- (5-hydroxymethyl-imidazol-1-ylmethyl) -benzonitrile

3.36 g (13.2 mmol) of the compound of Preparation Example 6-4 were dissolved in 160 mL of methanol, and then 3.60 g (26.3 mmol) of K ₂ CO ₃ was added thereto, and the mixture was stirred at room temperature for 20 minutes. The organic solvent was removed by distillation under reduced pressure, extracted with 250 ml of ethyl acetate, and then subjected to column chromatography with dichloromethane / methanol to obtain 2.55 g (yield: 91%, molecular weight: 213) of the title compound.

Preparation Example 7 Preparation of 3-imidazol-1-yl-propanol

7-1) Preparation of 3-imidazol-1-yl-propionic acid methyl ester

5.0 g (73.4 mmol) of imidazole and 12.6 g (148.6 mmol) of methyl acrylate were dissolved in acetonitrile and then stopped for 8 hours. Acetonitrile and excess methyl acrylate were removed by distillation under reduced pressure, ethyl acetate was added, and the mixture was washed with saturated sodium chloride solution. The organic solvent was removed by distillation under reduced pressure to obtain 11.1 g (yield: 90%, molecular weight: 168) of the title compound.

7-2) Preparation of 3-imidazol-1-yl-propanol

After dissolving 11.0 g (66 mmol) of the compound prepared in Preparation Example 7-1) in 250 mL of tetrahydrofuran, 2.6 g (66 mmol) of lithium aluminum hydride was added thereto, and the mixture was stopped for 1 hour. 1N sodium hydroxide solution was added and extracted with ethyl acetate. The organic solvent was removed by distillation under reduced pressure to obtain 7.7 g (yield: 93%, molecular weight: 126) of the title compound.

Example 1: 4- [5- (3-naphthalen-1-yl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -benzonitrile (1) Manufacture

0.053 g (0.24 mmol) of the compound of Preparation Example 1, 0.051 g (0.24 mmol) of the compound of Preparation Example 6 and 0.079 g (0.30 mmol) of triphenylphosphine were dissolved in 10 ml of tetrahydrofuran, followed by diethyl azodica. 0.047 mL (0.30 mmol) of the carboxylate was added and stirred for 24 hours. After tetrahydrofuran was removed by distillation under reduced pressure, column chromatography was carried out with a mixed solvent of methanol and dichloromethane (3:97) to obtain 0.081 g (yield: 80%, molecular weight: 421.5) of the title compound.

Example 2: 3- [3- (4-chloro-benzyl) -3H-imidazol-4-ylmethyl] -1-naphthalen-1-yl-imidazolidine-2,4-dione (2) Produce

2-1) Preparation of 1- (4-chlorobenzyl) -5-hydroxymethyl-imidazole

Except for using 4-chlorobenzylamine instead of 4-bromobenzylamine in Preparation Example 5 the reaction was carried out in the same manner to obtain the title compound in 54% yield.

2-2) Preparation of 3- [3- (4-chloro-benzyl) -3H-imidazol-4-ylmethyl] -1-naphthalen-1-yl-imidazolidine-2.4-dione

The reaction was carried out in the same manner as in Example 1 using 0.046 g (0.21 mmol) of the compound of Example 2-1) and 0.043 g (0.19 mmol) of the compound of Preparation Example 1 to obtain 0.07 g (yield: 85%, of the title compound). Molecular weight: 430.9) was obtained.

Example 3: 4- [5- (3-naphthalen-1-yl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -peperidin-1- Preparation of Carboxylic Acid Benzyl Ester (3)

The reaction was carried out in the same manner as in Example 1 using 0.090 g (0.23 mmol) of the compound of Preparation Example 4 and 0.035 g (0.16 mmol) of the compound of Preparation Example 1 to obtain 0.07 g of the title compound (yield 81%, molecular weight: 537.6) was obtained.

Example 4: 4- [5- (3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -benzonitrile (4 Manufacturing

4-1) Preparation of (naphthalen-1-ylmethyl-amino) -acetic acid ethyl ester

Except for using 1- naphthylmethylamine in place of 1- naphthylamine in Preparation Example 1-1 to give the title compound in 90% yield.

4-2) Preparation of 1- (naphthalen-1-ylmethyl) -imidazolidine-2,4-dione

The reaction was carried out in the same manner as in Preparation Example 1-2) using the compound of Example 4-1), to obtain the title compound in 92% yield.

4-3) Preparation of 4- [5- (3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -benzonitrile

0.050 g (0.21 mmol) of the compound of Example 4-2 and 0.047 g (0.22 mmol) of the compound of Preparation Example 6 were reacted in the same manner as in Example 1, to 0.077 g of the title compound (yield: 84%, molecular weight: 435) Got.

Example 5: 4- [5- (3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -piperidine-1 Preparation of carboxylic acid benzyl ester (5)

0.050 g (0.21 mmol) of the compound of Example 4-2 and 0.072 g (0.22 mmol) of the compound of Preparation Example 4 were reacted in the same manner as in Example 1, and 0.10 g (yield: 87%, molecular weight: 551).

Example 6: {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine- Preparation of 4-yl} -acetic acid ethyl ester (6)

1.10 g (3.37 mmol) of the compound of Preparation Example 2 and 0.86 g (4.06 mmol) of the compound of Preparation Example 6 were reacted in the same manner as in Example 1 to obtain 1.58 g (yield: 90%, molecular weight: 521) of the title compound.

Example 7: {1- [3- (4-Cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine- Preparation of 4-yl} -acetic acid (7)

0.7 g (1.34 mmol) of the compound of Example 6 were dissolved in a mixed solvent of tetrahydrofuran, methanol, and water (3: 2: 1), and then 0.2 g (2.68 mmol) of lithium hydroxide monohydrate was added thereto for 1 hour. Stirred. The solvent was removed by distillation under reduced pressure to obtain 0.66 g (yield: 95%, molecular weight: 516) of the title compound.

Example 8 {1- [3- (4-Cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine- Preparation of (4S) -yl} -acetic acid methyl ester (8)

0.287 g (0.920 mmol) of the compound of Preparation Example 3 and 0.215 g (1.01 mmol) of the compound of Preparation Example 6 were reacted in the same manner as in Example 1 to obtain 0.364 g (yield: 78%, molecular weight: 507) of the title compound.

Example 9: 4- {5- [4- (2-morpholin-4-yl-2-oxo-ethyl) -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine- Preparation of 1-ylmethyl] -imidazol-1-ylmethyl} -benzonitrile (9)

0.073 g (0.14 mnol) of the compound of Example 7, 0.018 mL (0.21 mmol) of morpholine and 0.038 g (0.28 mmol) of N-hydroxybenzotriazole were dissolved in 10 mL of dimethylformamide, followed by 1-ethyl- 0.04 g (0.21 mmol) of (3-dimethylaminopropyl) carbodiide was added and stirred for 2 hours. Dimethylformamide was removed by distillation under reduced pressure, and 20 ml of ethyl acetate was added thereto. The organic layer was washed with water and saturated sodium bicarbonate solution, and ethyl acetate was removed by distillation under reduced pressure. Column chromatography was performed on a mixed solvent of methanol and dichloromethane (3:97) to obtain 0.061 g (yield: 78%, molecular weight: 562) of the title compound.

Example 10: 4- {5- (4S)-[4- (2-morpholin-4-yl-2-oxo-ethyl) -3-naphthalen-1-ylmethyl-2,5-dioxo-alme Preparation of dazolidin-1-ylmethyl] -imidazol-1-ylmethyl} -benzonitrile (10)

0.071 g (0.14 mmol) of the compound of Example 8 was reacted in the same manner as in Example 9, using a compound obtained in the same manner as in Example 7 to obtain 0.059 g (yield: 75%, molecular weight: 562) of the title compound. )

Example 11: 2- {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazoli Din-4-yl} -N- (N, N-dimethylaminoethyl) -acetamide (11)

The reaction was carried out in the same manner as in Example 9 using 0.073 g (0.14 mmol) of the compound of Example 7 and 0.016 mL (0.18 mmol) of N, N-dimethylaminoethylamine, yielding 0.060 g of the title compound (yield: 78%, Molecular weight: 550).

Example 12: 2- {1- [3- (4-Bromo-benzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imida Preparation of zolidin-4-yl} -N- (2-methoxyethyl) -N-methyl-acetamide (12)

12-1) 2- {1- [3- (4-Bromo-benzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl -2.5-dioxo-imidazolidine Preparation of 4-yl} -acetic acid

Using the compound of Preparation 5 and the compound of Preparation 2 was carried out the same method as Example 1 and Example 7 to obtain the title compound in the yield of 83%.

12-2) 2- {1- [3- (4-Bromo-benzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imida Preparation of zolidin-4-yl} -N- (2-methoxyethyl) -N-methyl-acetamide

Example 12-1) using the same method as Example 9 using 0.055 g (0.10 mmol) of the compound of Example 12-1 and 0.011 g (0.12 mm0 l) of N-methyl-2-methoxyethylamine, yielding 0.045 g of the title compound (yield: 73%, molecular weight: 617).

Example 13: 4- (5- {4- [2- (4-methylpiperazin-1-yl) -2-oxo-ethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo- Preparation of imidazolidin-1-ylmethyl} -imidazol-1-ylmethyl) -benzonitrile (13)

The reaction of 0.14 g (0.28 mmol) of Example 8 in the same manner as in Example 7 was carried out in the same manner as in Example 9, using 0.044 mL (0.40 mmol) of N-methylpiperazine and the title compound. 0.11 g (yield 71%, molecular weight: 575.7) of a compound was obtained.

Example 14 (2S)-(2- {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-di Preparation of oxo-imidazolidin-4-yl} -acetamino) -4-methylsulfanyl-butanoic acid methyl ester (14)

The reaction was carried out in the same manner as in Example 9 using 0.16 g (0.31 mmol) of the compound of Example 7 and 0.066 g (0.35 mmol) of (L) -methionine methylester hydrochloride, yielding 0.17 g (yield: 84% of the title compound). , Molecular weight: 638) was obtained.

Example 15: (2S)-(2- {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-di Preparation of oxo-imidazolidin-4-yl} -acetamino) -4-methylsulfanyl-butanoic acid (15)

The reaction was carried out in the same manner as in Example 7 using the compound of Example 14 to give the title compound in a yield of 95%.

Example 16: Preparation of 3- (3-imidazol-1-yl-propyl) -1-naphthalen-1-yl-imidazolidine-2,4-dione (16)

Using 0.10 g (0.44 mmol) of the compound of Preparation Example 1 and 0.055 g (0.44 mmol) of the compound of Preparation Example 7, the reaction was carried out in the same manner as in Example 1, to obtain 0.13 g (yield: 91%, molecular weight: 334) of the title compound. )

Experimental Example 1: Analysis of Ras farnesyl transferase inhibitory activity

In this experiment an improved method of Pompriano (Pompliano et al., Biochemistry, 1992, 31, 3800) was used. In other words, Ras farnesyl transferase prepared by genetic recombination technology was used, and the Ras substrate (Ras-CVLS) protein was previously reported (see Chung et al., Bichimica et Biophysica Acta, 1992, 278, 1129). Purified according to the use.

The enzymatic reaction was carried out in 50 μl 50 mM sodium hippie buffer containing 25 mmol potassium chloride, 25 mmol magnesium chloride, 10 mmol DTT and 50 μmol zinc chloride, 1.5 μmol Ras substrate protein, 0.15 μmol Tritium-panesyl pyrophosphate and 4.5 nmol of panesyl transferase were used.

The reaction was stopped by adding a fascil enzyme and continuing the reaction at 37 DEG C for 30 minutes, and then adding 1 ml of an ethanol solution containing 1 mol of hydrochloric acid. The resulting precipitate was adsorbed onto a GF / B filter using a hopper harvester (hopper #FH 225V) for filter binding, washed with ethanol, and the dried filter was measured for radioactivity using an LKB beta counter. The enzyme titer assay was performed in the state of substrate unsaturation where the concentrations of Ras substrate protein and panesyl transferase showed quantitative titers. The synthesized compounds were dissolved in dimethyl sulfoxide (DMSO) solvent and added within 5% of the total reaction solution. Enzyme inhibition was evaluated. Enzyme inhibitory activity was expressed as a percentage of the amount of farnesyl introduced in the presence of the sample to the farnesyl introduced into the Ras substrate protein in the absence of the sample, and the concentration that inhibits 50% enzyme activity was determined as the IC 50 of each sample. Geranylgeranyl transferase for evaluating the selective inhibitory activity of the sample was purified from the cerebellum by modifying the method of Shaver et al. (Schaber et al. J. Biol Chem., 1990, 265 14701) Experiments were carried out using geranylgeranyl pyrophosphate and Ras-CVIL substrate protein, which are specific substrates of geranylgeranyl transferase under enzymatic reaction and similar conditions. The experimental results are shown in Table 2 below.

Experimental Example 2 Analysis of Inhibitory Effect of Intracellular Ras Farnesyl Transferase

In this experiment, Rat2 cell line expressing C-Harver-Ras protein with transgenic activity by mutation and H-Ras transformed with binding protein substituted with H-Ras substituted with polybasic lysine domain of carboxy terminus of K-Ras ( Reference: Korean Patent Application No. 97-14409) was used, and the experimental method was performed by modifying the method of Decrue et al. (See Declue. JE et. Al., Cancer Research. 1991, 51, 712) as follows. It was.

The transformed Rat2 fibroblast cell line was grown to a density of 50% or more by dispensing 3 × 10 ⁵ cells into a 60 mm cell culture dish and incubating for 48 hours in a 37 ° C. cell incubator, and then treated with a sample. In this case, dimethyl sulfoxide (DMSO) was used as the sample solvent, and dimethyl sulfoxide concentration of 1% was used in both the control group and the test group. Four hours after the sample was treated, methionine labeled with 150 μCi of radioisotope ( ³⁵ S) per 1 ml of medium was added thereto, and the cells were washed with physiological saline after 20 hours of incubation. 1 ml of cold cell lysis buffer solution (5 mmol magnesium chloride, 1 mmol DTT, 1% NP 40, 1 mmol EDTA, 1 mmol PMSF, 2 μmol lupetin, 2 μmol pepstatin A and 2 μmol antipain After dissolving the cells by adding 50 mM sodium hippie buffer solution, the supernatant in which the cells were lysed was obtained by high-speed centrifugation (12,000 g x 5 minutes). The radioisotope labeling amount of the supernatant was measured and normalized to obtain quantitative results in the immunoprecipitation reaction. Subsequently, a monoclonal antibody, Y13-259 (see Furth, ME et al., J. Virol., 1982, 43, 294), which specifically binds to Ras protein, was added to the reaction solution and reacted at 4 ° C. for 15 hours. I was. To this solution, a protein A (Agarose suspension) bound to the immunoglobulin of rats derived from Goth was added thereto, reacted at 4 ° C. for 1 hour, and then the immunoreactivity precipitate was removed to remove the nonspecific binding material. Wash with buffer (50 mM tris chloride buffer containing 50 mmol sodium chloride, 0.5% sodium dioxycholate, 0.5% NP 40 and 0.1% SDS). In order to analyze the precipitate using the electrophoresis method, the precipitate was immersed in an electrophoretic sample buffer and subjected to electrophoresis using 13.5% SDS polyacrylamide gel. After electrophoresis, the gel was fixed, dried, and then exposed to an X-ray film and developed for printing. From the experimental results, the inhibitory effect of intracellular Ras farnesyl transferase was determined by measuring the intensity of the non-bound bands with the farnesyl bound band to the Ras protein and determining the sample concentration at which the farnesyl binding was inhibited by 50% as CIC ₅₀ . It was. Table 2 shows the inhibitory effect of the representative compounds according to the present invention. Here, IC ₅₀ is data obtained as a result of performing Experimental Example 1, CIC ₅₀ is data obtained as a result of performing Experimental Example 2. It has been shown that the compounds according to the invention inhibit the action of farnesyl transferase at IC ₅₀ below 10 μM and CIC ₅₀ below 100 μM.

TABLE 2

As described above, the compound of the present invention can be usefully used as an anticancer agent by inhibiting the action of the farnesyl transferase, an enzyme that transfers farnesyl groups to the Ras protein.

Claims (4)

Imidazolidine-2,4-dione derivatives of Formula 1 below, stereochemical isomers, pharmaceutically acceptable salts or esters thereof: Formula 1 Where R ₁ is aromatic having 6 to 10 carbon atoms; Aromatics having 6 to 10 carbon atoms substituted by alkyl having 1 to 4 carbon atoms; Aromatics having 6 to 10 carbon atoms substituted by halogen; Aromatics having 6 to 10 carbon atoms including nitrogen or sulfur atoms; Or alkyl having 1 to 4 carbon atoms substituted by aromatic atoms having 6 to 10 carbon atoms, R ₂ represents an amino acid group or any one selected from the group of the following structural formulas; From here, A is 1) hydrogen; 2) alkyl of 1 to 4 carbon atoms; 3) 6 to 10 carbon atoms substituted by halogen, cyano, nitro, carboxylate (COOR), amide, thioamide, sulfanyl (SR), alkoxy (OR) having 1 to 4 carbon atoms or alkyl having 1 to 4 carbon atoms Aromatic of; 4) aromatics having 6 to 10 carbon atoms containing nitrogen or sulfur atoms substituted by halogen, cyano, nitro, COOR, amide, thioamide, SR or alkyl having 1 to 4 carbon atoms in the ring; 5) alkyl of 1 to 4 carbon atoms substituted by an aromatic of 3) or 4) above (R in SR, OR and COOR means hydrogen or alkyl of 1 to 4 carbon atoms); Or 6) group Indicates, From here, E represents hydrogen or FG, where F represents CH ₂ , C═O or SO ₂ , and G is alkyl having 1 to 4 carbon atoms unsubstituted or substituted by hydrogen, phenyl or biphenyl; Alkoxy having 1 to 4 carbon atoms; Phenyl; benzyl; Benzyloxy; Or amino substituted or unsubstituted by alkyl, phenyl or benzyl having 1 to 4 carbon atoms, B and C each independently represent hydrogen, halogen or alkyl having 1 to 4 carbon atoms, n represents 0 to 4, R3 is hydrogen, alkyl of 1-4 groups Indicates, From here, D is unsubstituted or substituted by C1-C4 alkoxy, hydroxy, amino, morpholine, thiomorpholine, piperazine unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms, Alkoxyalkylamine having 2 to 8 carbon atoms, an alkyl moiety substituted or unsubstituted by an alkylamino having 1 to 4 carbon atoms, and an alkylamine or amino acid residue having 1 to 4 carbon atoms. Indicates, m represents 0-2. The method of claim 1, 4- [5- (3-naphthalen-1-yl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -benzonitrile (1), 3- [3- (4-chlorobenzyl) -3H-imidazol-4-ylmethyl] -1-naphthalen-1-yl-imidazolidine-2,4-dione (2), 4- [5- (3-naphthalen-1-yl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -piperidine-1-carboxylic acid benzyl Ester (3), 4- [5- (3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1-ylmethyl] -benzonitrile (4), 4- [5- (3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-1-ylmethyl) -imidazol-1 ylmethyl] -piperidine-1-carboxylic acid benzyl Ester (5), {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-4-yl} Acetic acid ethyl ester (6), {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-4-yl} Acetic acid (7), {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine- (4S)- Japanese} acetic acid methyl ester (8), 4- {5- [4- (2-morpholin-4-yl-2-oxo-ethyl) -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidin-1-ylmethyl ] -Imidazol-1-ylmethyl} -benzonitrile (9), 4- {5- (4S)-[4- (2-morpholin-4-yl-2-oxo-ethyl) -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine- 1-ylmethyl] -imidazol-1-ylmethyl} -benzonitrile (10), 2- {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine-4- Ni-N- (N, N-dimethylaminoethyl) -acetamide (11), 2- {1- [3- (4-bromobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine-4- Japanese} -N- (2-methoxyethyl) -N-methylacetamide (12), 4- (5- {4- [2- (4-methylpiperazin-1-yl) -2-oxo-ethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imidazolidine -1-ylmethyl} -imidazol1-ylmethyl) -benzonitrile (13), (2S)-(2- {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imida Zolidin-4-yl} -acetamino) -4-methylsulfanyl-butanoic acid methyl ester (14), (2S)-(2- {1- [3- (4-cyanobenzyl) -3H-imidazol-4-ylmethyl] -3-naphthalen-1-ylmethyl-2,5-dioxo-imida Zolidin-4-yl} -acetamino) -4-methylsulfanyl-butanoic acid (15) or 3- (3-imidazol-1-yl-propyl) -1-naphthalen-1-yl-imidazolidine-2,4-dione (16). (a) preparing a compound of Formula 1 by reacting a compound of Formula 2 with a Mitsunobu compound of Formula 3; (b) preparing a compound of Formula 1a by reacting a compound of Formula 4 with Mitsunobu with a compound of Formula 3; (c) hydrolyzing the compound of formula 1a obtained in step (b) to prepare a compound of formula 1b, and then coupling and amidating the compound of formula 5 to prepare a compound of formula 1c. Process for preparing a compound of formula 1 as defined in claim 1: Formula 2 Formula 3 Formula 4 Formula 1a Formula 1b Formula 5 Formula 1c In the above formula, R ¹ , R ² and R ³ are as defined in claim 1, D 'is the same as D, but not hydroxy or alkoxy. An anticancer composition comprising the imidazolidine-2,4-dione derivative according to claim 1 as an active ingredient together with a pharmaceutically acceptable carrier.